{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:30:00Z","timestamp":1793309400568,"version":"4.5.0"},"reference-count":319,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202429"],"award-info":[{"award-number":["82202429"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LBY23H080001"],"award-info":[{"award-number":["LBY23H080001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022KY236"],"award-info":[{"award-number":["2022KY236"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2023RC131"],"award-info":[{"award-number":["2023RC131"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Innovation"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xinn.2026.101359","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:22:04Z","timestamp":1774714924000},"page":"101359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["PROTAC-mediated regulation of programmed cell death: From molecular mechanisms to therapeutic breakthroughs"],"prefix":"10.1016","volume":"7","author":[{"given":"Hangqi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoli","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7519-8531","authenticated-orcid":false,"given":"Jing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xinn.2026.101359_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fmolb.2020.00021","article-title":"Resolving the Complexity of Ubiquitin Networks","volume":"7","author":"Kliza","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.xinn.2026.101359_bib2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/17460441.2019.1659242","article-title":"PROTACs- a game-changing technology","volume":"14","author":"Konstantinidou","year":"2019","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202100270","article-title":"Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic","volume":"23","author":"Hu","year":"2022","journal-title":"Chembiochem"},{"key":"10.1016\/j.xinn.2026.101359_bib4","doi-asserted-by":"crossref","first-page":"8428","DOI":"10.1021\/acs.jmedchem.3c00302","article-title":"Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41418-020-00703-w","article-title":"The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities","volume":"28","author":"Damgaard","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xinn.2026.101359_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.736","article-title":"The role of ubiquitination in health and disease","volume":"5","author":"Liao","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.xinn.2026.101359_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/procel\/pwad045","article-title":"The ubiquitin codes in cellular stress responses","volume":"15","author":"Sheng","year":"2024","journal-title":"Protein Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.xinn.2026.101359_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105280","article-title":"The ubiquitin-proteasome system and learning-dependent synaptic plasticity \u2013 A 10 year update","volume":"152","author":"Patrick","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.xinn.2026.101359_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12943-024-02046-3","article-title":"Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xinn.2026.101359_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41580-019-0101-y","article-title":"The proteostasis network and its decline in ageing","volume":"20","author":"Hipp","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.molcel.2025.01.016","article-title":"Combinatorial mapping of E3 ubiquitin ligases to their target substrates","volume":"85","author":"Suiter","year":"2025","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajpath.2018.09.004","article-title":"Protein Degradation and the Pathologic Basis of Disease","volume":"189","author":"Hanna","year":"2019","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.xinn.2026.101359_bib14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/abbs\/gmaa053","article-title":"The application of ubiquitin ligases in the PROTAC drug design","volume":"52","author":"Chen","year":"2020","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.xinn.2026.101359_bib15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","article-title":"Advancing targeted protein degradation for cancer therapy","volume":"21","author":"Dale","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xinn.2026.101359_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11010-013-1939-5","article-title":"Efficient induction of apoptosis by proteasome inhibitor: bortezomib in the human breast cancer cell line MDA-MB-231","volume":"389","author":"Kr\u0119towski","year":"2014","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.xinn.2026.101359_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12272-023-01455-0","article-title":"Ubiquitin-proteasome system as a target for anticancer treatment-an update","volume":"46","author":"Kim","year":"2023","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.xinn.2026.101359_bib18","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.3390\/cancers14184492","article-title":"CRL4(CRBN) E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma","volume":"14","author":"Barankiewicz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xinn.2026.101359_bib19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.xinn.2026.101359_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.133680","article-title":"Progress of proteolysis-targeting chimeras (PROTACs) delivery system in tumor treatment","volume":"275","author":"Fan","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.xinn.2026.101359_bib21","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.xinn.2026.101359_bib22","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1002\/anie.201307761","article-title":"Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system","volume":"53","author":"Buckley","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.xinn.2026.101359_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.xinn.2026.101359_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib25","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.chembiol.2014.09.001","article-title":"Small-molecule inhibitors of protein-protein interactions: progressing toward the reality","volume":"21","author":"Arkin","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib26","article-title":"Targeted protein degradation in cancers: Orthodox PROTACs and beyond","volume":"4","author":"Li","year":"2023","journal-title":"Innovation"},{"key":"10.1016\/j.xinn.2026.101359_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.xinn.2026.101359_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.872729","article-title":"Overcoming Cancer Drug Resistance Utilizing PROTAC Technology","volume":"10","author":"Burke","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib30","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xinn.2026.101359_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.xinn.2026.101359_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70024","article-title":"Programmed cell death: molecular mechanisms, biological functions, diseases, and therapeutic targets","volume":"5","author":"Qian","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.xinn.2026.101359_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cell.2023.11.044","article-title":"Cell death","volume":"187","author":"Newton","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib34","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3390\/cells10071765","article-title":"Programmed Cell Death in Health and Disease","volume":"10","author":"Gibellini","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.xinn.2026.101359_bib35","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13045-022-01392-3","article-title":"Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research","volume":"15","author":"Tong","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xinn.2026.101359_bib36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tcb.2020.11.005","article-title":"Programmed Cell Death: Central Player in Fungal Infections","volume":"31","author":"Camilli","year":"2021","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib37","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1039\/D1CS00762A","article-title":"Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation","volume":"51","author":"Chen","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.xinn.2026.101359_bib38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-024-03237-y","article-title":"Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer","volume":"43","author":"Guo","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xinn.2026.101359_bib39","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.98450.3","article-title":"Identification of suitable target\/E3 ligase pairs for PROTAC development using a rapamycin-induced proximity assay (RiPA)","volume":"13","author":"Adhikari","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.xinn.2026.101359_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.xinn.2026.101359_bib41","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/bdrc.21096","article-title":"Thalidomide-induced teratogenesis: History and mechanisms","volume":"105","author":"Vargesson","year":"2015","journal-title":"Birth Defects Res. C Embryo Today."},{"key":"10.1016\/j.xinn.2026.101359_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56177-5","article-title":"Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xinn.2026.101359_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101359_bib45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd3627","article-title":"Targeting IAP proteins for therapeutic intervention in cancer","volume":"11","author":"Fulda","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib47","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1021\/acs.jmedchem.4c02569","article-title":"Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders","volume":"68","author":"Feller","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib48","article-title":"Proteolysis Targeting Chimeras (PROTACs): An Innovative Strategy for Targeted Protein Degradation and Disease Treatment","volume":"3","author":"Xia","year":"2024","journal-title":"Int. J. Drug Discov. Pharmacol."},{"key":"10.1016\/j.xinn.2026.101359_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-025-00826-7","article-title":"Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation","volume":"13","author":"Zhao","year":"2025","journal-title":"Biomarker Res."},{"key":"10.1016\/j.xinn.2026.101359_bib50","doi-asserted-by":"crossref","first-page":"22622","DOI":"10.1021\/jacs.2c09255","article-title":"Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets","volume":"144","author":"Xiong","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xinn.2026.101359_bib51","doi-asserted-by":"crossref","first-page":"8634","DOI":"10.1021\/acs.jmedchem.5c00295","article-title":"Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation","volume":"68","author":"Deng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib52","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.chembiol.2024.03.011","article-title":"Repurposing AS1411 for constructing ANM-PROTACs","volume":"31","author":"Fu","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib53","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1021\/jacs.4c14650","article-title":"Discovery of a Natural Ent-Kaurene Diterpenoid Oridonin as an E3 Ligase Recruiter for PROTACs","volume":"147","author":"Huang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xinn.2026.101359_bib54","first-page":"119","article-title":"Development of PROTAC Degrader Drugs for Cancer","volume":"9","author":"Vetma","year":"2024","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib55","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/anie.201914396","article-title":"Structure-Based Design of a Macrocyclic PROTAC","volume":"59","author":"Testa","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.xinn.2026.101359_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70258","article-title":"Advancing Design Strategy of PROTACs for Cancer Therapy","volume":"6","author":"Luo","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.xinn.2026.101359_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xinn.2026.101359_bib58","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib59","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib60","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1021\/acs.jcim.2c00982","article-title":"DRlinker: Deep Reinforcement Learning for Optimization in Fragment Linking Design","volume":"62","author":"Tan","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.xinn.2026.101359_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-21502-8","article-title":"PRosettaC outperforms AlphaFold3 for modeling PROTAC ternary complexes","volume":"15","author":"Schulz","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xinn.2026.101359_bib62","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acsmedchemlett.4c00189","article-title":"Interplay of PROTAC Complex Dynamics for Undruggable Targets: Insights into Ternary Complex Behavior and Linker Design","volume":"15","author":"Kumar","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.xinn.2026.101359_bib63","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1021\/acs.jcim.5c00102","article-title":"Construction of PROTAC-Mediated Ternary Complex Structure Distribution Profiles Using Extensive Conformational Search","volume":"65","author":"Kudo","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.xinn.2026.101359_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado6492","article-title":"Mechanism of degrader-targeted protein ubiquitinability","volume":"10","author":"Crowe","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xinn.2026.101359_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-61272-5","article-title":"SE(3)-equivariant ternary complex prediction towards target protein degradation","volume":"16","author":"Xue","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101359_bib66","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.xinn.2026.101359_bib67","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41401-024-01312-w","article-title":"A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects","volume":"45","author":"Xu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.xinn.2026.101359_bib68","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/acs.jmedchem.9b01566","article-title":"Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib69","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.chembiol.2018.11.006","article-title":"Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML","volume":"26","author":"Brand","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.931772","article-title":"The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants","volume":"13","author":"Ye","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xinn.2026.101359_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129838","article-title":"Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities","volume":"109","author":"Zhang","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.xinn.2026.101359_bib72","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial","volume":"29","author":"Ackerman","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.xinn.2026.101359_bib73","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1535-7163.MCT-23-0655","article-title":"Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader","volume":"24","author":"Snyder","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107234","article-title":"PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer","volume":"205","author":"Zhang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.xinn.2026.101359_bib75","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4\/6 or PI3K\/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xinn.2026.101359_bib76","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib77","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.csbj.2019.01.006","article-title":"Bivalent Ligands for Protein Degradation in Drug Discovery","volume":"17","author":"Scheepstra","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.xinn.2026.101359_bib78","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","article-title":"Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib79","doi-asserted-by":"crossref","first-page":"20495","DOI":"10.1021\/acs.jmedchem.4c01946","article-title":"Discovery of SD-436: A Potent, Highly Selective and Efficacious STAT3 PROTAC Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib80","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1038\/s41388-024-03121-1","article-title":"BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression","volume":"43","author":"Kong","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.xinn.2026.101359_bib81","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.neo.2019.10.003","article-title":"Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells","volume":"21","author":"Otto","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.xinn.2026.101359_bib82","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.3390\/ijms23073560","article-title":"Protein Kinases: Function, Substrates, and Implication in Diseases","volume":"23","author":"Cipak","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib83","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.3390\/molecules28124672","article-title":"Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical","volume":"28","author":"Kong","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.xinn.2026.101359_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.181","article-title":"Small molecule inhibitors targeting the cancers","volume":"3","author":"Liu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.xinn.2026.101359_bib85","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib86","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1038\/s41467-024-52966-3","article-title":"Principles of paralog-specific targeted protein degradation engaging the C-degron E3 KLHDC2","volume":"15","author":"Scott","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101359_bib87","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.xinn.2026.101359_bib88","first-page":"1","article-title":"The Activity of Novel BCR-ABL Small-Molecule Degraders Containing Pyrimidine Rings and Their Role in Overcoming Drug Resistance","volume":"2022","author":"Zhang","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.xinn.2026.101359_bib89","article-title":"Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations","volume":"5","author":"Wang","year":"2024","journal-title":"Innovation"},{"key":"10.1016\/j.xinn.2026.101359_bib90","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41467-021-21159-7","article-title":"Mutant-selective degradation by BRAF-targeting PROTACs","volume":"12","author":"Alabi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101359_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2019.110452","article-title":"Targeting Nuclear Receptors with PROTAC degraders","volume":"493","author":"Flanagan","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.xinn.2026.101359_bib92","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-physiol-021909-135917","article-title":"Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics","volume":"72","author":"Huang","year":"2010","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.xinn.2026.101359_bib93","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/aps.2014.120","article-title":"ROR nuclear receptors: structures, related diseases, and drug discovery","volume":"36","author":"Zhang","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.xinn.2026.101359_bib94","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0165-6147(00)01548-0","article-title":"Nuclear receptor ligand-binding domains three-dimensional structures, molecular interactions and pharmacological implications","volume":"21","author":"Bourguet","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib95","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xinn.2026.101359_bib96","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s44324-024-00013-6","article-title":"Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease","volume":"2","author":"Antwi","year":"2024","journal-title":"NPJ Metab. Health Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib97","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3390\/receptors3040022","article-title":"Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers","volume":"3","author":"Silva-C\u00e1zares","year":"2024","journal-title":"Receptors"},{"key":"10.1016\/j.xinn.2026.101359_bib98","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1535-7163.MCT-20-0417","article-title":"Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy","volume":"20","author":"Lee","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib99","doi-asserted-by":"crossref","first-page":"8902","DOI":"10.1021\/jacs.1c03852","article-title":"TF-PROTACs Enable Targeted Degradation of Transcription Factors","volume":"143","author":"Liu","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xinn.2026.101359_bib100","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41392-024-02004-x","article-title":"Targeted protein degradation: advances in drug discovery and clinical practice","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib101","doi-asserted-by":"crossref","first-page":"910","DOI":"10.15252\/msb.20167238","article-title":"Transcription factor family-specific DNA shape readout revealed by quantitative specificity models","volume":"13","author":"Yang","year":"2017","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib102","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1016\/j.molcel.2024.08.010","article-title":"Integrated multi-omics analysis of zinc-finger proteins uncovers roles in RNA regulation","volume":"84","author":"Gosztyla","year":"2024","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib103","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/stem.1609","article-title":"STAT3 Phosphorylation at Tyrosine 705 and Serine 727 Differentially Regulates Mouse ESC Fates","volume":"32","author":"Huang","year":"2014","journal-title":"Stem Cell."},{"key":"10.1016\/j.xinn.2026.101359_bib104","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/srep17663","article-title":"Multiple regulation pathways and pivotal biological functions of STAT3 in cancer","volume":"5","author":"Yuan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xinn.2026.101359_bib106","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib107","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-Myc","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib108","doi-asserted-by":"crossref","first-page":"9334","DOI":"10.1021\/jacs.3c02619","article-title":"c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer","volume":"145","author":"Li","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xinn.2026.101359_bib109","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-21-0385","article-title":"EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma","volume":"12","author":"Durbin","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib111","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of Therapeutic Antitumor Monoclonal Antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.xinn.2026.101359_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115073","article-title":"RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges","volume":"201","author":"Won Lee","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xinn.2026.101359_bib113","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s11658-022-00348-2","article-title":"CRISPR\/Cas9 gene editing: a new approach for overcoming drug resistance in cancer","volume":"27","author":"Vaghari-Tabari","year":"2022","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.xinn.2026.101359_bib114","article-title":"Direct evidence of CRISPR-Cas9-mediated mitochondrial genome editing","volume":"3","author":"Bi","year":"2022","journal-title":"Innovation"},{"key":"10.1016\/j.xinn.2026.101359_bib115","doi-asserted-by":"crossref","first-page":"9278","DOI":"10.1021\/acs.jmedchem.3c00449","article-title":"Molecular Glue Discovery: Current and Future Approaches","volume":"66","author":"Dewey","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Mart\u00edn-Acosta","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib117","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xinn.2026.101359_bib118","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101359_bib119","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf6249","article-title":"Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras","volume":"382","author":"Ahn","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.xinn.2026.101359_bib120","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: Cargo-Specific Degraders Using Selective Autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib121","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/15548627.2020.1718362","article-title":"Targeting selective autophagy by AUTAC degraders","volume":"16","author":"Takahashi","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.xinn.2026.101359_bib122","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.3390\/ijms23116206","article-title":"Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein-Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases","volume":"23","author":"Li","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112954","article-title":"Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer","volume":"210","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib124","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.3390\/ijms22126213","article-title":"Small-Molecule Inhibitors Targeting Proteasome-Associated Deubiquitinases","volume":"22","author":"Moon","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib125","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/07388551.2021.1874281","article-title":"Stability testing in monoclonal antibodies","volume":"41","author":"Kaur","year":"2021","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.xinn.2026.101359_bib126","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","article-title":"RNA interference in the era of nucleic acid therapeutics","volume":"42","author":"Jadhav","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xinn.2026.101359_bib127","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-022-01518-8","article-title":"Current applications and future perspective of CRISPR\/Cas9 gene editing in cancer","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xinn.2026.101359_bib128","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic \u2014 a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101359_bib129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s43556-021-00043-2","article-title":"E3 ubiquitin ligases: styles, structures and functions","volume":"2","author":"Yang","year":"2021","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.xinn.2026.101359_bib130","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202308186","article-title":"Degradation-Based Protein Profiling: A Case Study of Celastrol","volume":"11","author":"Ni","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.679120","article-title":"Targeting Protein Kinases Degradation by PROTACs","volume":"9","author":"Yu","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib132","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1021\/jacs.8b08008","article-title":"Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation","volume":"140","author":"Cromm","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xinn.2026.101359_bib133","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.xinn.2026.101359_bib134","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1000","article-title":"Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positivehuman epidermal growth factor receptor 2 (HER2)\u2013negative advanced breast cancer Results of the global, randomized, phase 3 VERITAC-2 study","volume":"43","author":"Hamilton","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101359_bib135","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/pharmaceutics17060744","article-title":"Molecular Design of Novel Protein-Degrading Therapeutics Agents Currently in Clinical Trial","volume":"17","author":"Kacin","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xinn.2026.101359_bib136","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70181","article-title":"Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults","volume":"18","author":"Agarwal","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib137","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54409-5","article-title":"Critical assessment of LC3\/GABARAP ligands used for degrader development and ligandability of LC3\/GABARAP binding pockets","volume":"15","author":"Schwalm","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101359_bib138","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xinn.2026.101359_bib139","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","article-title":"Necroptosis, pyroptosis and apoptosis: an intricate game of cell death","volume":"18","author":"Bertheloot","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.xinn.2026.101359_bib140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41580-023-00689-6","article-title":"A guide to cell death pathways","volume":"25","author":"Yuan","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib141","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41580-020-0270-8","article-title":"Emerging connectivity of programmed cell death pathways and its physiological implications","volume":"21","author":"Bedoui","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib142","doi-asserted-by":"crossref","first-page":"R1292","DOI":"10.1016\/j.cub.2020.09.068","article-title":"Ferroptosis","volume":"30","author":"Tang","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib143","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/s12935-021-02420-x","article-title":"FTH promotes the proliferation and renders the HCC cells specifically resist to ferroptosis by maintaining iron homeostasis","volume":"21","author":"Hu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.xinn.2026.101359_bib144","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41419-021-04128-2","article-title":"CISD3 inhibition drives cystine-deprivation induced ferroptosis","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib145","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41419-020-2298-2","article-title":"Ferroptosis: past, present and future","volume":"11","author":"Li","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib146","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","article-title":"Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects","volume":"9","author":"Ru","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib147","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/s12951-024-02808-7","article-title":"Ferroptosis-inducing nanomedicine and targeted short peptide for synergistic treatment of hepatocellular carcinoma","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.xinn.2026.101359_bib148","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41420-022-01212-0","article-title":"GPX4-independent ferroptosis\u2014a new strategy in disease\u2019s therapy","volume":"8","author":"Ma","year":"2022","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101483","article-title":"Identification of Frataxin as a regulator of ferroptosis","volume":"32","author":"Du","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib150","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib151","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41420-024-01825-7","article-title":"Ferroptosis: Emerging mechanisms, biological function, and therapeutic potential in cancer and inflammation","volume":"10","author":"Jin","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib152","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.bbrc.2020.10.083","article-title":"Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis","volume":"534","author":"Li","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.xinn.2026.101359_bib153","doi-asserted-by":"crossref","first-page":"8872","DOI":"10.1038\/s41598-023-35978-9","article-title":"GPX4 overexpressed non-small cell lung cancer cells are sensitive to RSL3-induced ferroptosis","volume":"13","author":"Kim","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xinn.2026.101359_bib154","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3892\/ijmm.2023.5248","article-title":"Advances in the study of regulators of ferroptosis in head and neck squamous cell carcinoma","volume":"51","author":"Yang","year":"2023","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.xinn.2026.101359_bib155","doi-asserted-by":"crossref","first-page":"16712","DOI":"10.1021\/acs.jmedchem.4c01518","article-title":"Heat Shock Protein 90 Interactome-Mediated Proteolysis Targeting Chimera (HIM-PROTAC) Degrading Glutathione Peroxidase 4 to Trigger Ferroptosis","volume":"67","author":"Dong","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115343","article-title":"Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells","volume":"254","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116110","article-title":"A potent GPX4 degrader to induce ferroptosis in HT1080 cells","volume":"265","author":"Song","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115393","article-title":"Structure-activity relationship study of RSL3-based GPX4 degraders and its potential noncovalent optimization","volume":"255","author":"Zheng","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib159","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/acsmedchemlett.3c00571","article-title":"ZX703: A Small-Molecule Degrader of GPX4 Inducing Ferroptosis in Human Cancer Cells","volume":"15","author":"Hu","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.xinn.2026.101359_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115329","article-title":"A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer","volume":"206","author":"Li","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.xinn.2026.101359_bib161","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41420-025-02491-z","article-title":"Targeting epigenetic and post-translational modifications of NRF2: key regulatory factors in disease treatment","volume":"11","author":"Yang","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102122","article-title":"Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram\/copper-induced ferroptosis","volume":"46","author":"Ren","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib163","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s11658-022-00383-z","article-title":"Inhibition of CISD2 promotes ferroptosis through ferritinophagy-mediated ferritin turnover and regulation of p62-Keap1-NRF2 pathway","volume":"27","author":"Li","year":"2022","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.xinn.2026.101359_bib164","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1021\/acs.jmedchem.2c01909","article-title":"ARE-PROTACs Enable Co-degradation of an Nrf2-MafG Heterodimer","volume":"66","author":"Ji","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib165","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.freeradbiomed.2018.12.011","article-title":"DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin","volume":"131","author":"Du","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.xinn.2026.101359_bib166","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12964-024-01520-1","article-title":"Regulation of NCOA4-mediated iron recycling ameliorates paraquat-induced lung injury by inhibiting ferroptosis","volume":"22","author":"Du","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.xinn.2026.101359_bib167","doi-asserted-by":"crossref","first-page":"12521","DOI":"10.1021\/acs.jmedchem.4c00403","article-title":"Discovery of a NCOA4 Degrader for Labile Iron-Dependent Ferroptosis Inhibition","volume":"67","author":"Ji","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib168","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12964-022-01025-9","article-title":"The Warburg effect modulates DHODH role in ferroptosis: a review","volume":"21","author":"Amos","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.xinn.2026.101359_bib169","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202300871","article-title":"Exploiting Cancer Vulnerabilities by Blocking of the DHODH and GPX4 Pathways: A Multifunctional Bodipy\/PROTAC Nanoplatform for the Efficient Synergistic Ferroptosis Therapy","volume":"12","author":"Yao","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.xinn.2026.101359_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103788","article-title":"DHODH-mediated mitochondrial redox homeostasis: a novel ferroptosis regulator and promising therapeutic target","volume":"85","author":"Cao","year":"2025","journal-title":"Redox Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib171","article-title":"Dual-Programmable Semiconducting Polymer NanoPROTACs for Deep-Tissue Sonodynamic-Ferroptosis Activatable Immunotherapy","volume":"20","author":"Wang","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.xinn.2026.101359_bib172","article-title":"Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib173","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","article-title":"Pyroptosis: mechanisms and diseases","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib174","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1016\/j.molcel.2021.09.003","article-title":"Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity","volume":"81","author":"Hou","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib175","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41423-022-00905-x","article-title":"Role of pyroptosis in inflammation and cancer","volume":"19","author":"Wei","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.xinn.2026.101359_bib176","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.cell.2023.04.025","article-title":"A 360 degrees view of the inflammasome: Mechanisms of activation, cell death, and diseases","volume":"186","author":"Barnett","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib177","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41419-023-06382-y","article-title":"The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstacles","volume":"14","author":"Hu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib178","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.xinn.2026.101359_bib179","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13046-025-03366-y","article-title":"Role of inflammasomes in cancer immunity mechanisms and therapeutic potential","volume":"44","author":"Singh","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xinn.2026.101359_bib180","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40364-025-00771-5","article-title":"Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities","volume":"13","author":"Miao","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xinn.2026.101359_bib181","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1021\/acs.jmedchem.1c01948","article-title":"Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib182","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41388-024-03013-4","article-title":"Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma","volume":"43","author":"Wu","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.xinn.2026.101359_bib183","article-title":"A PROTAC Augmenter for Photo-Driven Pyroptosis in Breast Cancer","volume":"36","author":"Huang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.xinn.2026.101359_bib184","doi-asserted-by":"crossref","first-page":"9815","DOI":"10.1021\/jacs.3c01852","article-title":"Small-Molecule Ferritin Degrader as a Pyroptosis Inducer","volume":"145","author":"Chen","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xinn.2026.101359_bib185","doi-asserted-by":"crossref","first-page":"8464","DOI":"10.1021\/acs.jmedchem.3c00118","article-title":"Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy","volume":"66","author":"Sang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib186","article-title":"Precision targeting of STING: Challenges, innovations, and clinical outlook for cancer therapy","volume":"7","author":"Shi","year":"2026","journal-title":"Innovation"},{"key":"10.1016\/j.xinn.2026.101359_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102691","article-title":"STING mediates hepatocyte pyroptosis in liver fibrosis by Epigenetically activating the NLRP3 inflammasome","volume":"62","author":"Xiao","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib188","article-title":"Research and progress of cGAS\/STING\/NLRP3 signaling pathway: a mini review","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101359_bib189","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2147\/DDDT.S501773","article-title":"Regulation and Function of the cGAS-STING Pathway: Mechanisms, Post-Translational Modifications, and Therapeutic Potential in Immunotherapy","volume":"19","author":"Chen","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib190","article-title":"cGAS-STING pathway in ischemia-reperfusion injury: a potential target to improve transplantation outcomes","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101359_bib191","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275408","article-title":"Novel insight into cGAS-STING pathway in ischemic stroke: from pre- to post-disease","volume":"14","author":"Ma","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101359_bib192","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/svn-2023-002320","article-title":"STING mediates microglial pyroptosis via interaction with NLRP3 in cerebral ischaemic stroke","volume":"9","author":"Li","year":"2024","journal-title":"Stroke Vasc. Neurol."},{"key":"10.1016\/j.xinn.2026.101359_bib193","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41392-025-02216-9","article-title":"STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib194","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41419-024-06600-1","article-title":"STING contributes to lipopolysaccharide-induced tubular cell inflammation and pyroptosis by activating endoplasmic reticulum stress in acute kidney injury","volume":"15","author":"Cao","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112990","article-title":"PROTAC based STING degrader attenuates acute colitis by inhibiting macrophage M1 polarization and intestinal epithelial cells pyroptosis mediated by STING-NLRP3 axis","volume":"141","author":"Xu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.xinn.2026.101359_bib196","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1505255","article-title":"Precision-engineered PROTACs minimize off-tissue effects in cancer therapy","volume":"11","author":"Shi","year":"2024","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.xinn.2026.101359_bib197","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-025-02178-y","article-title":"Deep insight into cytokine storm: from pathogenesis to treatment","volume":"10","author":"Nie","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib198","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrm3737","article-title":"Regulated necrosis: the expanding network of non-apoptotic cell death pathways","volume":"15","author":"Vanden Berghe","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib199","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41418-018-0212-6","article-title":"Pyroptosis versus necroptosis: similarities, differences, and crosstalk","volume":"26","author":"Frank","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xinn.2026.101359_bib200","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s12276-021-00634-7","article-title":"Necroptosis molecular mechanisms: Recent findings regarding novel necroptosis regulators","volume":"53","author":"Seo","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xinn.2026.101359_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117196","article-title":"Recognition of necroptosis: From molecular mechanisms to detection methods","volume":"178","author":"Zhu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.xinn.2026.101359_bib202","article-title":"Excessive nucleic acid R-loops induce mitochondria-dependent epithelial cell necroptosis and drive spontaneous intestinal inflammation","volume":"121","author":"Yang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xinn.2026.101359_bib203","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/BCJ20240569","article-title":"Inhibition of RIPK1 or RIPK3 kinase activity post ischemia-reperfusion reduces the development of chronic kidney injury","volume":"482","author":"Pefanis","year":"2025","journal-title":"Biochem. J."},{"key":"10.1016\/j.xinn.2026.101359_bib204","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","article-title":"Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase","volume":"148","author":"Sun","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib205","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.320","article-title":"Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis","volume":"4","author":"Steinhart","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib206","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/s41598-024-53207-9","article-title":"Identification of a novel macrophage-related prognostic signature in colorectal cancer","volume":"14","author":"Lin","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xinn.2026.101359_bib207","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3390\/biom13050820","article-title":"The Induction Mechanism of Ferroptosis, Necroptosis, and Pyroptosis in Inflammatory Bowel Disease, Colorectal Cancer, and Intestinal Injury","volume":"13","author":"Zhou","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.xinn.2026.101359_bib208","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41419-020-02941-9","article-title":"Reduction in MLKL-mediated endosomal trafficking enhances the TRAIL-DR4\/5 signal to increase cancer cell death","volume":"11","author":"Park","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib209","doi-asserted-by":"crossref","first-page":"11216","DOI":"10.1021\/acs.jmedchem.3c00665","article-title":"PROTACs Targeting MLKL Protect Cells from Necroptosis","volume":"66","author":"Rathje","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib210","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.7150\/thno.71400","article-title":"Loss of MLKL ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and hepatic stellate cell activation","volume":"12","author":"Guo","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.xinn.2026.101359_bib211","doi-asserted-by":"crossref","first-page":"15353","DOI":"10.1021\/acs.jmedchem.4c00949","article-title":"Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib212","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/s41467-022-29670-1","article-title":"Development of NanoLuc-targeting protein degraders and a universal reporter system to benchmark tag-targeted degradation platforms","volume":"13","author":"Grohmann","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101359_bib213","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/j.immuni.2024.04.025","article-title":"A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death","volume":"57","author":"Mannion","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.xinn.2026.101359_bib214","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41419-024-07325-x","article-title":"TRAF2 and RIPK1 redundantly mediate classical NFkappaB signaling by TNFR1 and CD95-type death receptors","volume":"16","author":"Wagner","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib215","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1021\/jacs.3c13646","article-title":"Structurally Specific Z-DNA Proteolysis Targeting Chimera Enables Targeted Degradation of Adenosine Deaminase Acting on RNA 1","volume":"146","author":"Wang","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xinn.2026.101359_bib216","article-title":"Targeted Degradation of ZBP1 with Covalent PROTACs for Anti-Inflammatory Treatment of Infections","volume":"64","author":"Huang","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.xinn.2026.101359_bib217","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55006-2","article-title":"Development of a RIPK1 degrader to enhance antitumor immunity","volume":"15","author":"Yu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101359_bib218","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1007\/s10495-023-01882-w","article-title":"Role of APR3 in cancer: apoptosis, autophagy, oxidative stress, and cancer therapy","volume":"28","author":"Zhang","year":"2023","journal-title":"Apoptosis"},{"key":"10.1016\/j.xinn.2026.101359_bib219","first-page":"148","volume":"9","author":"Voss","year":"2020","journal-title":"The essentials of developmental apoptosis. F1000Res"},{"key":"10.1016\/j.xinn.2026.101359_bib220","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3390\/biomedicines11041196","article-title":"Apoptosis\u201450 Years after Its Discovery","volume":"11","author":"Capela e","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.xinn.2026.101359_bib221","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1007\/s12035-023-03433-5","article-title":"A Review on Caspases: Key Regulators of Biological Activities and Apoptosis","volume":"60","author":"Sahoo","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.xinn.2026.101359_bib222","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1097-2765(02)00482-3","article-title":"Mechanisms of Caspase Activation and Inhibition during Apoptosis","volume":"9","author":"Shi","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib223","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: from pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xinn.2026.101359_bib224","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/jpm11060463","article-title":"Review of Venetoclax in CLL, AML and Multiple Myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.xinn.2026.101359_bib225","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41467-024-46922-4","article-title":"Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL","volume":"15","author":"Nayak","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101359_bib226","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3324\/haematol.2022.281915","article-title":"Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells","volume":"108","author":"Jia","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.xinn.2026.101359_bib227","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.xinn.2026.101359_bib228","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1158\/0008-5472.CAN-23-2804","article-title":"BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs","volume":"83","author":"Skwarska","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.xinn.2026.101359_bib229","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.112","article-title":"Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis","volume":"49","author":"Lee","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xinn.2026.101359_bib230","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1158\/1535-7163.MCT-24-0306","article-title":"KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors","volume":"24","author":"Chutake","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib231","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-22-1131","article-title":"Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer","volume":"13","author":"Adams","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib232","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116367","article-title":"Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer","volume":"270","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib233","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.apsb.2020.11.022","article-title":"Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer","volume":"11","author":"He","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.xinn.2026.101359_bib234","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s12276-020-0455-4","article-title":"Autophagy as a decisive process for cell death","volume":"52","author":"Jung","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xinn.2026.101359_bib235","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41419-023-06154-8","article-title":"Autophagy: Regulator of cell death","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib236","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the Pathogenesis of Disease","volume":"132","author":"Levine","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib237","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41420-024-02224-8","article-title":"Lipids associated with autophagy: mechanisms and therapeutic targets","volume":"10","author":"Jarocki","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib238","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41419-021-03996-y","article-title":"DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism","volume":"12","author":"Du","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib239","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41422-025-01085-9","article-title":"Oncogenic RAS induces a distinctive form of non-canonical autophagy mediated by the P38-ULK1-PI4KB axis","volume":"35","author":"Wang","year":"2025","journal-title":"Cell Res."},{"key":"10.1016\/j.xinn.2026.101359_bib240","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s11427-023-2563-6","article-title":"Isowalsuranolide targets TrxR1\/2 and triggers lysosomal biogenesis and autophagy via the p53-TFEB\/TFE3 axis","volume":"68","author":"Yang","year":"2025","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib241","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.734818","article-title":"TEOA Promotes Autophagic Cell Death via ROS-Mediated Inhibition of mTOR\/p70S6k Signaling Pathway in Pancreatic Cancer Cells","volume":"9","author":"Yang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib242","article-title":"Next questions of autophagy in neurodegenerative diseases: From mechanisms to therapeutics","volume":"7","author":"Luo","year":"2026","journal-title":"Innovation"},{"key":"10.1016\/j.xinn.2026.101359_bib243","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252312485","article-title":"Advances and Challenges in Gene Therapy for Neurodegenerative Diseases: A Systematic Review","volume":"25","author":"Garc\u00eda-Gonz\u00e1lez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib244","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1088575","article-title":"The role of autophagy in cardiovascular disease: Cross-interference of signaling pathways and underlying therapeutic targets","volume":"10","author":"Jiang","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.xinn.2026.101359_bib245","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41419-022-04906-6","article-title":"Mitochondrial autophagy: molecular mechanisms and implications for cardiovascular disease","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib246","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/cdd.2008.130","article-title":"Eating the enemy within: autophagy in infectious diseases","volume":"16","author":"Orvedahl","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xinn.2026.101359_bib247","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/acschembio.8b01016","article-title":"Rapid and Reversible Knockdown of Endogenously Tagged Endosomal Proteins via an Optimized HaloPROTAC Degrader","volume":"14","author":"Tovell","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib248","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41467-022-28520-4","article-title":"The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system","volume":"13","author":"Ji","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101359_bib249","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113328","article-title":"Effective degradation of EGFR(L858R+T790M) mutant proteins by CRBN-based PROTACs through both proteosome and autophagy\/lysosome degradation systems","volume":"218","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112781","article-title":"Discovery of potent small molecule PROTACs targeting mutant EGFR","volume":"208","author":"Zhao","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib251","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1021\/acs.jmedchem.2c00345","article-title":"Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras","volume":"65","author":"Yu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib252","first-page":"38","article-title":"Intracellular accumulation of tau inhibits autophagosome formation by activating TIA1-amino acid-mTORC1 signaling","volume":"9","author":"Li","year":"2022","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.xinn.2026.101359_bib253","first-page":"24","article-title":"PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives","volume":"1","author":"Inuzuka","year":"2022","journal-title":"Acta Mater. Med."},{"key":"10.1016\/j.xinn.2026.101359_bib254","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.xinn.2026.101359_bib255","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102584","article-title":"Targeted protein degradation: expanding the technology to facilitate the clearance of neurotoxic proteins in neurodegenerative diseases","volume":"102","author":"Wang","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.xinn.2026.101359_bib256","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins","volume":"375","author":"Tsvetkov","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.xinn.2026.101359_bib257","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/procel\/pwae003","article-title":"Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond","volume":"15","author":"Mao","year":"2024","journal-title":"Protein Cell"},{"key":"10.1016\/j.xinn.2026.101359_bib258","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","article-title":"Copper homeostasis and cuproptosis in health and disease","volume":"7","author":"Chen","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib259","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41420-025-02718-z","article-title":"Protein lipoylation in cancer: metabolic reprogramming and therapeutic potential","volume":"11","author":"Li","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib260","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114830","article-title":"The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease","volume":"163","author":"Wang","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.xinn.2026.101359_bib261","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41571-024-00876-0","article-title":"Targeting cuproplasia and cuproptosis in cancer","volume":"21","author":"Tang","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xinn.2026.101359_bib262","article-title":"Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor Immunotherapy","volume":"11","author":"Lu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib263","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.103007","article-title":"Inhibiting the compensatory elevation of xCT collaborates with disulfiram\/copper-induced GSH consumption for cascade ferroptosis and cuproptosis","volume":"69","author":"Zhang","year":"2024","journal-title":"Redox Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib264","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2025.154131","article-title":"Copper oxide nanoparticles induce pulmonary inflammation via triggering cellular cuproptosis","volume":"514","author":"Zhang","year":"2025","journal-title":"Toxicology"},{"key":"10.1016\/j.xinn.2026.101359_bib265","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s00204-022-03357-4","article-title":"CuO-NPs-triggered heterophil extracellular traps exacerbate liver injury in chicks by promoting oxidative stress and inflammatory responses","volume":"96","author":"Jiang","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.xinn.2026.101359_bib266","doi-asserted-by":"crossref","first-page":"10343","DOI":"10.1039\/C9SC04387J","article-title":"Self-triggered click reaction in an Alzheimer's disease model:in situbifunctional drug synthesis catalyzed by neurotoxic copper accumulated in amyloid-\u03b2 plaques","volume":"10","author":"Du","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101018","article-title":"Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance","volume":"72","author":"Wang","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.xinn.2026.101359_bib268","article-title":"A PROTAC-Based Cuproptosis Sensitizer in Lung Cancer Therapy","volume":"37","author":"Wang","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.xinn.2026.101359_bib269","first-page":"773","article-title":"From mechanism to application: programmed cell death pathways in nanomedicine-driven cancer therapies","volume":"52","author":"Zhang","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.xinn.2026.101359_bib270","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41420-020-00349-0","article-title":"The caspase-3\/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer","volume":"6","author":"Jiang","year":"2020","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib271","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.1090072","article-title":"p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa","volume":"302","author":"Villunger","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.xinn.2026.101359_bib272","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53-mediated activity during tumour suppression","volume":"520","author":"Jiang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101359_bib273","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","article-title":"Ferroptosis: Death by Lipid Peroxidation","volume":"26","author":"Yang","year":"2016","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib274","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","article-title":"BAP1 links metabolic regulation of ferroptosis to tumour suppression","volume":"20","author":"Zhang","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1390263","article-title":"Emerging role of immunogenic cell death in cancer immunotherapy","volume":"15","author":"Arimoto","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xinn.2026.101359_bib276","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib277","article-title":"Light-Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy","volume":"36","author":"Choi","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.xinn.2026.101359_bib278","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1016\/j.apsb.2025.06.028","article-title":"Activatable PROTAC nanoassembly for photodynamic PTP1B proteolysis enhances glioblastoma immunotherapy","volume":"15","author":"Jang","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.xinn.2026.101359_bib279","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1038\/s41388-021-02041-8","article-title":"BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade","volume":"40","author":"Tong","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.xinn.2026.101359_bib280","article-title":"Chemotherapy-Enabled Colorectal Cancer Immunotherapy of Self-Delivery Nano-PROTACs by Inhibiting Tumor Glycolysis and Avoiding Adaptive Immune Resistance","volume":"11","author":"Zhao","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib281","article-title":"Innovative PDK1-Degrading PROTACs Transform Cancer Aerobic Glycolysis and Induce Immunogenic Cell Death in Breast Cancer","volume":"5","author":"Deng","year":"2025","journal-title":"Exploration (Beijing)"},{"key":"10.1016\/j.xinn.2026.101359_bib282","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.ymthe.2025.02.013","article-title":"A BPTF-specific PROTAC degrader enhances NK cell-based cancer immunotherapy","volume":"33","author":"Li","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib283","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","article-title":"Antibody targeting of E3 ubiquitin ligases for receptor degradation","volume":"610","author":"Marei","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xinn.2026.101359_bib284","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody\u2013PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib285","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202501384","article-title":"Remodeling the Physicochemical and Pharmacokinetic Properties of PROTAC via Lipid Nanodisks for Cancer Therapy","volume":"12","author":"Pan","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib286","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-025-02444-z","article-title":"In vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib287","doi-asserted-by":"crossref","first-page":"165815","DOI":"10.1016\/j.cej.2025.165815","article-title":"Self-assembled dual-targeting nanoplatform for synergistic photodynamic and PROTAC-mediated metabolic starvation in triple-negative breast cancer","volume":"520","author":"Zhang K.","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.xinn.2026.101359_bib288","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41392-025-02405-6","article-title":"Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy","volume":"10","author":"Park","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib289","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41421-024-00711-x","article-title":"PROTAC for Bruton's tyrosine kinase degradation alleviates inflammation in autoimmune diseases","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib290","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107386","article-title":"Research progress of PROTACs for neurodegenerative diseases therapy","volume":"147","author":"Cai","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib291","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.tips.2024.10.006","article-title":"Development of PROTACs using computational approaches","volume":"45","author":"Ge","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib292","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2024.11.076","article-title":"PROTAC delivery in tumor immunotherapy: Where are we and where are we going?","volume":"378","author":"Li","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.xinn.2026.101359_bib293","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117967","article-title":"The application of PROTACs in immune-inflammation diseases","volume":"115","author":"Zhang","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib294","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41573-024-01051-x","article-title":"Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics","volume":"23","author":"Carter","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xinn.2026.101359_bib295","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43556-024-00239-2","article-title":"Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer","volume":"6","author":"Gu","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.xinn.2026.101359_bib296","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abn2707","article-title":"The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells","volume":"15","author":"Kurimchak","year":"2022","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xinn.2026.101359_bib297","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-023-01398-5","article-title":"Protein degradation: expanding the toolbox to restrain cancer drug resistance","volume":"16","author":"Ming","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xinn.2026.101359_bib298","doi-asserted-by":"crossref","first-page":"17691","DOI":"10.1039\/D4SC03555K","article-title":"Dual-ligand PROTACS mediate superior target protein degradation in vitro and therapeutic efficacy in vivo","volume":"15","author":"Chen","year":"2024","journal-title":"Chem. Sci."},{"key":"10.1016\/j.xinn.2026.101359_bib299","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","article-title":"Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma","volume":"13","author":"Ng","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101359_bib300","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.gendis.2022.03.004","article-title":"BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations","volume":"10","author":"Ma","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.xinn.2026.101359_bib301","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-021-01146-7","article-title":"Protein degradation technology: a strategic paradigm shift in drug discovery","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xinn.2026.101359_bib302","doi-asserted-by":"crossref","first-page":"511","DOI":"10.37349\/etat.2021.00061","article-title":"The clinical advances of proteolysis targeting chimeras in oncology","volume":"2","author":"Xie","year":"2021","journal-title":"Explor Target Antitumor Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib303","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/s41401-024-01266-z","article-title":"Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy","volume":"45","author":"Zou","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.xinn.2026.101359_bib304","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1021\/acsnano.4c16629","article-title":"Exosome Inspired Lipid Nanoparticles for Enhanced Tissue Penetration","volume":"19","author":"Bang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.xinn.2026.101359_bib305","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","article-title":"Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xinn.2026.101359_bib306","doi-asserted-by":"crossref","first-page":"18208","DOI":"10.1021\/jacs.5c04857","article-title":"Reactive Oxygen Species-Instructed Supramolecular Assemblies Enable Bioorthogonally Activatable Protein Degradation for Pancreatic Cancer","volume":"147","author":"Yao","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xinn.2026.101359_bib307","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1038\/s41467-023-42233-2","article-title":"Expanding PROTACtable genome universe of E3 ligases","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xinn.2026.101359_bib308","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1039\/D5CB00198F","article-title":"Identification of ligands for E3 ligases with restricted expression using fragment-based methods","volume":"6","author":"Waterson","year":"2025","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib309","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2019.02.048","article-title":"Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs","volume":"27","author":"Girardini","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib310","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s42003-025-08104-w","article-title":"Cellular parameters shaping pathways of targeted protein degradation","volume":"8","author":"Cardno","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib311","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1021\/acs.jmedchem.3c02371","article-title":"Uncovering PROTAC Sensitivity and Efficacy by Multidimensional Proteome Profiling: A Case for STAT3","volume":"67","author":"Suo","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib312","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s42003-020-0868-6","article-title":"Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2","volume":"3","author":"Mares","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xinn.2026.101359_bib313","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107984","article-title":"Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies","volume":"154","author":"Malarvannan","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.xinn.2026.101359_bib314","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104032","article-title":"The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation","volume":"29","author":"Sobierajski","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.xinn.2026.101359_bib315","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s11658-025-00693-y","article-title":"Beyond destruction: emerging roles of the E3 ubiquitin ligase Hakai","volume":"30","author":"Escuder-Rodr\u00edguez","year":"2025","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.xinn.2026.101359_bib316","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1186\/s12964-024-01871-9","article-title":"Disulfidptosis: a novel cell death modality induced by actin cytoskeleton collapse and a promising target for cancer therapeutics","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.xinn.2026.101359_bib317","article-title":"Hydrogen sulfide regulation in redox homeostasis and programmed cell death: mechanistic insights and implications in cancer","author":"Deng","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.xinn.2026.101359_bib318","article-title":"In Vivo Self-Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy","volume":"64","author":"Xie","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.xinn.2026.101359_bib319","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.7150\/thno.102531","article-title":"A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"}],"container-title":["The Innovation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675826001062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666675826001062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:22:49Z","timestamp":1783714969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666675826001062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":319,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666675826001062"],"URL":"https:\/\/doi.org\/10.1016\/j.xinn.2026.101359","relation":{},"ISSN":["2666-6758"],"issn-type":[{"value":"2666-6758","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PROTAC-mediated regulation of programmed cell death: From molecular mechanisms to therapeutic breakthroughs","name":"articletitle","label":"Article Title"},{"value":"The Innovation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xinn.2026.101359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Youth Innovation Co., Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101359"}}